Canadian Patent Allowance Received

Zecotek Receives Canadian Patent Allowance For LFS Scintillation Material

Vancouver, September 29, 2008 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I) today announced that the Canadian Patent Office has issued Notice of Allowance to Zecotek Imaging Systems Singapore Pte. Ltd., a wholly-owned subsidiary, for its LFS scintillation material. This application is identical to the LFS scintillation applications that have been issued or allowed in the U.S., Russia, China, Europe and Japan.

“Receiving the notice of allowance from the Canadian Patent Office is an important step in protecting our intellectual property and it offers another level of protection for our intellectual property across North America,” said Dr. A. F. Zerrouk, Chairman and CEO of Zecotek. “Due to our work with the University of Washington and with leading medical equipment manufacturers, our LFS scintillation material is now widely recognized as an important new material for enhancing the performance of a wide range of imaging devices, and in particular, for its impact with next generation Positron Emission Tomography (PET) medical imaging.”

Zecotek has developed and patented a new class of advanced materials targeted at the next-generation of PET, PET-CT and PET-MRI medical imaging scanners. When combined with Zecotek’s MAPD solid-state photo detectors, the new scintillation materials allows for medical imaging devices to have higher resolution, enhanced diagnosis, improved patient outcomes, faster patient throughput and lower unit costs.

Other medical applications for LFS are in micro-PET detectors, widely used in drug research, and in gamma cameras used for breast and prostate examinations. Non-medical applications include gamma ray detector systems for homeland security, geological surveying, materials analysis, high energy physics and nuclear stockpile monitoring.

About Zecotek

Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing leading-edge products: crystals, photo detectors, lasers, imaging and 3D display technologies, for medical, biotech, industrial, nanotech and atomic/molecular science applications. Founded in 2003, the company has three distinct operating divisions: imaging, lasers and 3D display and labs located in Canada, the United States, Singapore, Malaysia and Russia. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit Zecotek Photonics.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For product and technical information please contact:
Zecotek Photonics Inc.
[email protected]
T: (604) 827-5232

For investor information please contact:
Caliber Capital & Communications
T: (778) 327-6678
E: [email protected]

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website